Why Is the Global Urea Market Projected to Decline at a -0.8% CAGR Amid Shifting Agricultural Demand in China, India, the U.S., and Brazil? According to a new report from Intel Market Research, the global Urea market was valued at USD 110.97 billion in 2026 and is projected to reach USD 104.8 billion by 2034, exhibiting a CAGR of -0.8% during the forecast period (2025–2032). This nuanced growth dynamic is shaped by a complex interplay of persistent agricultural demand in developing regions, counterbalanced by market maturity, environmental pressures, and a gradual shift towards alternative products in more saturated markets. This trajectory remains critically important for global food production systems. https://www.intelmarketresearch.com/download-free-sample/16695/urea-market

What Is the Future of Brachytherapy Afterloaders? Growth Forecasts According to a newly published market research report by 24LifeSciences, global brachytherapy afterloaders market was valued at USD 92.2 million in 2024 and is projected to reach USD 102 million by 2031, growing at a compound annual growth rate (CAGR) of 1.5% during the forecast period 2025-2031. A brachytherapy afterloader is a sophisticated medical device used to deliver targeted internal radiation therapy for cancer treatment. These systems are the technological backbone of modern brachytherapy, automating the precise placement and removal of radioactive sources directly inside or next to tumors. This targeted approach minimizes radiation exposure to healthy surrounding tissues and medical staff while delivering highly concentrated radiation doses to cancerous cells. These devices are critically important in treating prostate, gynecological, breast, and other cancers where precise radiation delivery is essential for optimal patient outcomes. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6426/brachytherapy-afterloaders-market-market-market

Top 10 Companies Driving Innovation in the Airway Management Devices Market According to a newly published market research report by 24LifeSciences, global airway management devices market was valued at USD 1.165 billion in 2025 and is projected to grow from USD 1.17 billion in 2026 to reach USD 1.556 billion by 2034, growing at a compound annual growth rate (CAGR) of 4.3% during the forecast period. Airway management devices are critical medical instruments used to maintain or restore a patient's airway patency, ensuring adequate ventilation and oxygenation when the natural airway is compromised. This category includes essential devices such as endotracheal tubes (ETTs), which are inserted into the trachea, and laryngeal mask airways (LMAs), which sit in the hypopharynx. Other crucial devices in this segment are Guedel airways and tracheostomy tubes. Their established role in securing the airway during surgery, emergency care, and critical illness continues to underpin their fundamental importance in anesthesiology, emergency medicine, and intensive care. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/801/airway-management-devices-market

Stem Cell Banking Market Growth Analysis: Opportunities & Forecasts According to a newly published market research report by 24LifeSciences, global stem cell banking market was valued at USD 1,761 Million in 2025 and is projected to grow from USD 1,896 million in 2026 to reach USD 2,943 Million by 2034, growing at a compound annual growth rate (CAGR) of 7.8% during the forecast period. Stem cell banking is the process of collecting, processing, and cryogenically preserving stem cells from sources like umbilical cord blood, cord tissue, and adult tissues for potential future therapeutic use. This service, often termed a biological insurance policy, plays an increasingly crucial role in regenerative medicine, offering potential treatments for a wide array of conditions from blood cancers like leukemia and lymphoma to genetic disorders and potential future applications in neurological and autoimmune diseases. Its importance is underscored by the growing arsenal of stem cell-based therapies entering clinical practice. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/4282/stem-cell-banking-market-market

Hydroxycarbamide Market’s CAGR of 6.1%: Leaders in Oncology & Hematology According to a newly published market research report by 24LifeSciences, global hydroxycarbamide market was valued at USD 226 million in 2025 and is projected to grow from USD 240 million in 2026 to reach USD 338 million by 2034, growing at a compound annual growth rate (CAGR) of 6.1% during the forecast period. Hydroxycarbamide, clinically known as hydroxyurea, is a foundational antineoplastic and antimetabolite medication that functions by inhibiting ribonucleotide reductase, a crucial enzyme for DNA synthesis. This mechanism positions it as a cornerstone therapy for several hematologic conditions. Its primary applications include the management of sickle cell disease, where it significantly reduces the frequency of painful crises and acute chest syndrome, as well as the treatment of specific cancers like chronic myelogenous leukemia, polycythemia vera, and essential thrombocythemia. Its established efficacy in cytoreduction and symptom management continues to underpin its critical importance in hematology and oncology. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/663/hydroxycarbamide-market-market

What Is the Future of Diabetic Foot and Pressure Ulcers Market? Growth Forecasts According to a newly published market research report by 24LifeSciences, global diabetic foot ulcers and pressure ulcers market is valued at USD 2.09 billion in 2026 and is projected to reach USD 2.72 billion by 2034, growing at a compound annual growth rate (CAGR) of 3.9% during the forecast period. Diabetic foot ulcers (DFUs) and pressure ulcers (PUs) represent significant and costly complications of chronic conditions, requiring advanced wound care management. DFUs, occurring primarily on the plantar surface of the foot in diabetic patients, are notoriously difficult to heal and carry a high risk of infection and amputation. Pressure ulcers, also known as pressure injuries or bedsores, result from prolonged pressure on the skin and underlying tissue, particularly affecting patients with limited mobility. The established clinical protocols for managing these complex wounds continue to underpin the critical importance of specialized wound care products and therapies in both hospital and community settings. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9456/diabetic-foot-ulcers-and-pressure-ulcers-market

What Is the Future of the Gastrointestinal Therapeutics Market? Growth Forecasts According to a newly published market research report by 24LifeSciences, global gastrointestinal therapeutics market is valued at USD 35,410 million in 2026 and is projected to reach USD 51,860 million by 2034, growing at a compound annual growth rate (CAGR) of 5.7% during the forecast period. Gastrointestinal therapeutics comprise a critical class of pharmaceuticals designed to treat a wide range of disorders affecting the digestive system, from the esophagus to the colon. This includes prevalent conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and inflammatory bowel disease (IBD). The therapeutic arsenal includes well-established drugs like proton pump inhibitors, biologics, and antacids, commercially available under brands such as Aciphex (rabeprazole) and Prilosec (omeprazole). The sustained efficacy and expanding applications of these treatments continue to underpin their importance in both primary care and specialized gastroenterology practice. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8881/gastrointestinal-therapeutics-market

How Is the Global Fish Compound Premix Market Expanding at a 6.4% CAGR Through 2034? Intel Market Research, the global Fish Compound Premix market was valued at USD 1,021 million in 2026 and is projected to reach USD 1,598 million by 2034, growing at a steady CAGR of 6.4% during the forecast period. In 2025, global production reached approximately 512,800 metric tons, reflecting the increasing importance of aquaculture nutrition in global food security initiatives. https://www.intelmarketresearch.com/fish-compound-premix-market-27513

Dermatoscope Market to Reach USD 82.6 Million by 2032 | Growth Trends & Insights According to a newly published market research report by 24LifeSciences, global dermatoscope market is valued at USD 41.4 million in 2026 and is projected to reach USD 82.6 million by 2034, growing at a compound annual growth rate (CAGR) of 10.6% during the forecast period. A dermatoscope is a vital non-invasive diagnostic instrument used in dermatoscopy for examining skin lesions with enhanced visualization. This handheld device employs magnification and specialized lighting systems to reveal subsurface skin structures invisible to the naked eye. Modern dermatoscopes increasingly utilize polarized light technology which eliminates the need for contact fluids, allowing clinicians to examine pigment networks, vascular patterns, and other morphological features critical for accurate diagnosis of skin cancers like melanoma and various dermatological conditions. Its established role in improving diagnostic accuracy continues to underpin its importance in dermatological practice and primary care settings worldwide. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/6685/dermatoscope-market-market

Protein Microarray Market Growth Analysis: Opportunities, Challenges & Forecasts According to a newly published market research report by 24LifeSciences, global protein microarray market is valued at USD 951.5 million in 2026 and is projected to reach USD 1.65 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.4% during the forecast period. A protein microarray, often termed a protein chip, is a high-throughput analytical platform designed to track the interactions, activities, and functions of thousands of proteins simultaneously. This powerful technology involves immobilizing an array of capture proteins such as antibodies, antigens, or peptides onto a solid support surface like a glass slide, nitrocellulose membrane, or microtitre plate. Its established efficacy in proteomic analysis continues to underpin its importance in biomarker discovery, drug development, and clinical diagnostics, transforming how researchers study complex biological systems. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/9116/protein-microarray-market

Global Generic Oncology Drugs Market Size & Growth Drivers Through 2034 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market

Generic Oncology Drugs Market’s CAGR of 6.3%: Leading Companies to Watch in 2026 According to a newly published market research report by 24LifeSciences, global generic oncology drugs market is valued at USD 35.2 billion in 2026 and is projected to reach USD 54.1 billion by 2034, growing at a compound annual growth rate (CAGR) of 6.3% during the forecast period. Generic oncology drugs are bioequivalent versions of brand-name cancer medications used after patent expirations, providing the same active ingredients, dosage, strength, and administration routes as their innovators. These drugs are broadly categorized into small molecule drugs and large molecule drugs (biosimilars), playing a critical role in making cancer treatment affordable and accessible globally. Their established efficacy and cost-effectiveness continue to underpin their importance in oncology care, particularly amid rising healthcare cost pressures. Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/8833/generic-oncology-drugs-market